SCHEMBL7181645

SCHEMBL7181645

CCOCCOc1ccc(PC(=O)c2c(OC)cccc2OC)cc1.[LiH]

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 5/20 0.43
LMNA P02545 4/20 0.43
L3MBTL1 Q9Y468 4/20 0.43
ALDH1A1 P00352 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
THRA P10827 1/20 0.41
APP P05067 2/20 0.39
ACACB O00763 1/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38
FFAR1 O14842 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189878 0.93 L3MBTL1 (0.46) SMN1; SMN2MAPTLMNAL3MBTL1ALDH1A1
SCHEMBL7177848 0.89 APP (0.43) SMN1; SMN2MAPTLMNAL3MBTL1ALDH1A1
SCHEMBL7183431 0.89 SMN1; SMN2 (0.46) SMN1; SMN2MAPTLMNAL3MBTL1ALDH1A1
SCHEMBL7187424 0.89 MAPT (0.46) SMN1; SMN2MAPTLMNAL3MBTL1ALDH1A1
SCHEMBL7187607 0.89 SMN1; SMN2 (0.46) SMN1; SMN2MAPTLMNAL3MBTL1ALDH1A1
SCHEMBL7183274 0.89 SMN1; SMN2 (0.58) SMN1; SMN2MAPTLMNAL3MBTL1ALDH1A1
SCHEMBL7187489 0.86 NR5A1 (0.46) SMN1; SMN2TP53
SCHEMBL7180731 0.85 NR5A1 (0.48) TP53
SCHEMBL7178012 0.85 L3MBTL1 (0.46) SMN1; SMN2LMNAL3MBTL1THRAACACB
SCHEMBL7185514 0.85 FFAR1 (0.43) SMN1; SMN2LMNAL3MBTL1THRAAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SMN1; SMN2 2939/4885MAPT 4870/4885LMNA 3241/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SMN1; SMN2 3105/4885MAPT 4859/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.